Authors: Natalia Oscoz-Susino, Matias D. Gómez-Elías, Claudio Bisioli, Marcos Horton, Mercedes Papayannis, Evelyn De Martino, Laura Kopcow, Martin Attie, Mariano Lavolpe, Carlos Carizza, Guillermina M. Luque, Carolina Baro Graf, Valentina Torres Monserrat, Estefania Navall, Mariano G. Buffone, and Dario Krapf.
This study evaluates the clinical utility of HyperSperm, a novel sperm capacitation technology, through a prospective sibling oocyte study involving 41 IVF patients. Semen samples from each patient were divided and processed using either standard preparation protocols or the HyperSperm protocol, and fertilization and embryo development outcomes were evaluated.
HyperSperm treatment was associated with significantly increased blastocyst development rates compared to standard preparation (55.6% vs. 47.9%, p=0.0038), resulting in a higher number of blastocysts per cycle. Furthermore, embryos generated with this technology showed improved morphological quality and a higher rate of euploidy as determined by preimplantation genetic testing (PGT-A). These findings support the translational potential of HyperSperm as a clinically relevant strategy to enhance early embryo competence and improve IVF efficiency.